Latest Recruitment News

Xref Limited has unveiled Xref.me, a pioneering platform that transforms recruitment by shifting to verified digital resumes at application, unlocking new pay-per-access revenue streams and expanding its enterprise SaaS funnel.

EMVision Medical Devices has ramped up recruitment in its pivotal FDA trial across eight hospitals and is nearing results from multiple pre-hospital studies, all while bolstering its cash position with a $3.8 million R&D tax refund and $6.6 million in grant funding.

Xref Limited reported a 54% jump in annual recurring revenue and a 28% reduction in operational expenses in Q3 FY26, driven by strong platform adoption and strategic integrations with global HR partners.

St Barbara has secured key environmental approvals to restart its Touquoy gold processing facility in Nova Scotia, targeting ore processing by the end of 2026. The project aims to produce 38,000 ounces of gold over 13 months, generating significant cash flow and local economic benefits.

The a2 Milk Company faces significant supply chain disruptions in China, dampening its infant formula sales and forcing a downgrade of its FY26 financial outlook despite robust demand.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) has received FDA Investigational New Drug clearance to initiate a pivotal clinical trial of its cell therapy Ryoncil in children with Duchenne Muscular Dystrophy, aiming to address inflammation-driven disease progression.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.

Emyria Limited has launched a targeted recruitment campaign in New South Wales to establish its fourth state-based clinical operation, aiming to tap into Australia's largest mental health market amid rising psychological injury claims.

Following ASIC's final inquiry report, ASX unveils a comprehensive transformation plan focusing on governance, leadership, and risk management, alongside a significant capital charge.

Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.

Cleo Diagnostics has completed blood sample collection for its pivotal U.S. clinical trial, advancing its Pre-Surgical Ovarian Cancer Test closer to FDA submission.

Paradigm Biopharmaceuticals has achieved 50% patient enrolment in its pivotal Phase 3 trial for injectable pentosan polysulfate sodium, advancing steadily towards an interim analysis expected in August 2026.